<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01969877</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT number 2012-001879-37</org_study_id>
    <secondary_id>2012-001879-37</secondary_id>
    <nct_id>NCT01969877</nct_id>
  </id_info>
  <brief_title>A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.</brief_title>
  <acronym>ARTSCANIII</acronym>
  <official_title>A Randomized Multicenter Phase III Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lund University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary endpoint in this study is to investigate if there is a difference in overall
      survival in patients with locally advanced head and neck cancer, randomized to either
      radiotherapy and cetuximab or radiotherapy and cisplatin. A second randomization is performed
      in patients with T3-T4 tumors; allocated radiotherapy either 68.0 Gy or 73.1 Gy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Every 3 month for 2 years, and every 6 month until 5 years for evaluation of overall survival</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">618</enrollment>
  <condition>Locally Advanced Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 1-4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cetuximab with a loading dose of 400 mg/m2 one week before start of radiotherapy, then 250 mg/m2 weekly during radiotherapy (tumor stage 3-4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy with a dose of 68.0 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 1-4).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiotherapy with a dose of 73.1 Gy in 34 fractions, and cisplatin weekly with a dose of 40 mg/m2 (tumor stage 3-4).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at least 18 years

          -  Histologically or cytologically confirmed , previous untreated head and neck squamous
             cell cancer of the oral cavity, hypopharynx, larynx or of the oral cavity aimed for
             unimodal treatment with radiotherapy with curative intent

          -  Tumor stage III and IV , but no evidence of distant metastases beyond the regional
             nodes in the neck

          -  WHO/Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  The patient must be expected to withstand radiotherapy combined with cisplatin or
             cetuximab

          -  The patient must be able to understand the information about the treatment and give a
             written informed concent to participate in the trial

          -  Adequate follow-up study must be possible; this will exclude a patient who is
             uncooperative

          -  Adequate renal function, creatinine clearance over 50 ml/min/1.73 estimated according
             to local practice at each study centre

        Exclusion Criteria:

          -  Previous malignant disease in the head and neck region, with exception for basal cell
             carcinoma or curatively treated squamous cell carcinoma of the skin with follow-up
             time of at least 3 years

          -  Concomitant or previous malignancies. Exceptions are adequately treated basal cell
             carcinoma or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix
             uteri, or other previous malignancy with a disease-free interval of at least 5 years

          -  Two or more synchronous primary head and neck squamous cell cancer at time of
             diagnosis

          -  Co-existing disease prejudicing survival (expected survival less than 6 months)

          -  Absolute neutrophil count less than 1.5 x 109/L

          -  Platelet count less than 100 x 109/L

          -  Bilirubin over 1.5 times upper limit of normal

          -  Aspartate aminotransferase (ASAT) or Alanine aminotransferase (ALAT) more than 3 times
             upper limit of normal

          -  Pregnancy or lactation

          -  Allergy to study drug or to the excipients in their formulation

          -  Neuropathy grade 2 or more according to Common terminology criteria for adverse events
             (CTCAE) v.4.0

          -  Hearing loss/tinnitus is a relative exclusion criteria; the responsible physician
             decides whether the patient may be included in the study

          -  Severe cardiac illness; myocardial infarction within 6 months prior to randomization,
             severe congestive heart failure, severe cardiomyopathy, ventricular arrythmia,
             unstable angina, uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Gebre-Medhin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Gebre-Medhin, MD, PhD</last_name>
    <phone>+46 46 17 75 20</phone>
    <email>maria.gebre-medhin@skane.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Iréne Schönström, RN</last_name>
    <phone>+46 46 17 85 59</phone>
    <email>irene.schonstrom@skane.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Bergström, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefan Bergström, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hedda Haugen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hedda Haugen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>County Hospital Ryhov</name>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mats Olin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mats Olin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Hospital</name>
      <address>
        <city>Karlstad</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta Lödén, MD</last_name>
    </contact>
    <investigator>
      <last_name>Britta Lödén, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Linköping</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Tytor, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maciej Tytor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska Universityhospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Signe Friesland, MD</last_name>
    </contact>
    <investigator>
      <last_name>Signe Friesland, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norrland University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Söderström, MD</last_name>
    </contact>
    <investigator>
      <last_name>Karin Söderström, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Västmanlands Hospital Västerås</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zuzana Lovasova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zuzana Lovasova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Örebro</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Reizenstein, MD</last_name>
    </contact>
    <investigator>
      <last_name>Johan Reizenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2013</study_first_submitted>
  <study_first_submitted_qc>October 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck cancer</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Human papilloma virus</keyword>
  <keyword>Health economy</keyword>
  <keyword>Biomarker investigations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

